Recent advances in disease-modifying therapies and the huge potential benefits of preventive multidomain interventions based on modifiable lifestyle and vascular factors provide new opportunities for early detection, prevention and treatment of Alzheimer’s disease (AD) and dementia. The AD-RIDDLE platform aims to transform how AD is detected and diagnosed, prevented and treated across healthcare settings. AD-RIDDLE centres around a toolbox platform concept, providing a series of validated tools at each key step to enable healthcare systems and practitioners to improve the management of AD and dementia across diverse patient populations.
The AD-RIDDLE toolbox platform will include a) community outreach tools to increase awareness/activation on AD prevention; b) combination of easily available, clinically validated biomarkers: digital cognitive tools and blood-based biomarkers, for early detection of AD dementia risk; c) validated algorithms supporting clinical decisions, to identify people who can benefit from specific preventive therapies (pharma and/or non-pharma) using precision prevention approach. The toolbox usability and efficacy with be tested in real-world settings. We expect that the AD-RIDDLE modular and flexible design can facilitate broad uptake from different healthcare systems, and its tools can advance research to develop cost-effective preventive therapies for AD, with scalability for other dementias.
The AD-RIDDLE project has received funding from the Innovative Health Initiative 2 Joint Undertaking (JU), under grant agreement No 101132933 (2024-2029). The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe, with Davos Alzheimer’s Collaborative, Combinostics OY., Cambridge Cognition Ltd., C2N Diagnostics LLC, and neotiv GmbH.
